Cleo Diagnostics (ASX:COV) Volatility: 62.79% (As of Jun. 26, 2026)


ASX:COV Cleo Diagnostics Ltd ASX:COV
17 GF Score
Price A$0.48
! 1 Warning Sign
View Full Analysis

What is Cleo Diagnostics Volatility?

Cleo Diagnostics ASX:COV 17 Volatility is 62.79% as of Jun. 26, 2026. GuruFocus rates ASX:COV with a GF Score™ of 17/100. The stock has 1 warning sign investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-06-26), Cleo Diagnostics's Volatility is 62.79%.

Cleo Diagnostics  (ASX:COV) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Cleo Diagnostics Volatility Related Terms

ASX:COV vs ABT, SYK, MDT: Volatility Comparison

For the Medical Devices subindustry, Cleo Diagnostics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cleo Diagnostics Volatility vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Volatility distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's Volatility falls into.


ASX:COV
17GF Score
Cleo Diagnostics Ltd ASX:COV
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cleo Diagnostics  (ASX:COV) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 62.79% mean?
Cleo Diagnostics (ASX:COV) has a Volatility of 62.79% as of Jun. 26, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Cleo Diagnostics and its competitors.
Is Cleo Diagnostics' Volatility too high?
Cleo Diagnostics' current Volatility is 62.79%. Overall, Cleo Diagnostics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Cleo Diagnostics' Volatility compare to ABT and SYK?
Cleo Diagnostics' Volatility of 62.79% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Medical Devices & Instruments company?
A good Volatility depends on the Medical Devices & Instruments industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Cleo Diagnostics and its competitors. Cleo Diagnostics's current Volatility is 62.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleo Diagnostics stock overvalued right now?
Cleo Diagnostics (ASX:COV) has a current Volatility of 62.79%. The current Volatility is 62.79%. Cleo Diagnostics' overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Cleo Diagnostics (ASX:COV), the current Volatility is 62.79% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cleo Diagnostics Business Description

Address 480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
17GF Score

Get the complete analysis for ASX:COV

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.48
Price